

## **AMENDMENTS TO THE SPECIFICATION**

**Please replace the existing Sequence Listing with the substitute Sequence Listing provided herewith.**

**Please amend the paragraphs on page 1, immediately following the title, as follows:**

### **Cross Reference to Related Applications**

This is a § 371 U.S. national stage of PCT/US02/10764, filed April 4, 2002, which was published in English under PCT Article 2(2), which is a continuation-in-part of, and claims the benefit of U.S. Patent Application 09/826,115, filed April 4, 2001, and issued as U.S. Patent No. 7,227,011. ~~Both applications are incorporated herein in their entirety.~~

~~This application is a continuation-in-part of, and claims the benefit of, U.S. application Ser. No. 09/826,115, filed Apr. 4, 2001, which status is pending and which is a continuation-in-part of, and claims the benefit of U.S. application Ser. No. 09/701,536, filed Nov. 29, 2000, which status is pending, and which U.S. application Ser. No. 09/701,536 is a national stage application of international application Serial No. PCT/US99/12298, filed June 3, 1999, which claims the benefit of Jun. 3, 1999 from, and which claims the benefit of, U.S. provisional application Ser. No. 60/087,908, filed Jun. 4, 1998, which applications are filed June 4, 1998. Each of the above-referenced applications is hereby incorporated by reference herein in their-its entirety by reference.~~

**Please amend the paragraph on page 15, lines 12-16, as follows:**

Figure 6 shows signal peptide probability of the pCBE1-14 (pCBE) predicted by the SignalP-HMM program (panel A; amino acids 1-39 of SEQ ID NO: 18). The signal peptide probability is improved by altering the c-region sequence at -4 and -2 positions (C-4G and G-2S) (panel B, JE-LSS-M; SEQ ID NO: 62), by shortening the n-region (panel C, JE-SS-ORI; SEQ ID NO: 63), or by a combination of both modifications (panel D, JE-SS-M; SEQ ID NO: 64).